Update on FSHD drug development programme

Published Date
11/09/2018
Category
Research
Orange box stating: Breaking news research

Facio Therapies has announced that it has selected several compounds as lead candidates for its FSHD drug development programme. The company will now further evaluate these compounds in the laboratory before selecting one or two for testing in clinical trials. Facio currently envisages its first clinical trial will start in 2021.

For more information, please read Facio Therapies’ press release.

If you have any questions about this news story or any other FSHD research, please contact the MDUK Research Line on 020 7803 4813 or email research@musculardystrophyuk.org.

Keep in touch